Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (111-120 of 175) with videos related to

Pageof 18
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 17, 2023
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitorsWilliam Shaffer, Ikei S Kobayashi, Daniel Sentana-Lledo, et al.
Blood|February 18, 2010
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cellsBritta Will, Tanya Siddiqi, Meritxell Alberich Jordà, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2007
Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590Daniel B Costa, Sigui Li, Olivier Kocher, et al.
The Journal of Infection|January 26, 2005
Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patientsSandra H A Bonon, Silvia M F Menoni, Cláudio L Rossi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungAndrew M Brunner, Daniel B Costa, Rebecca S Heist, et al.
Plos One|March 14, 2015
CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinomaYi Cai, Ayako Hirata, Sohei Nakayama, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2008
Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian populationHelen N Honma, Eduardo M De Capitani, Maurício W Perroud, et al.
Clinical Lung Cancer|April 26, 2015
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-ReviewSamuel J Klempner, Sai-Hong Ignatius Ou, Daniel B Costa, et al.
Targeted Oncology|May 6, 2014
EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patientsHelen N Honma, Maurício W Perroud, Maurício S T Leme, et al.
JTO Clinical and Research Reports|June 9, 2021
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsPedro E N S Vasconcelos, Carol Gergis, Hollis Viray, et al.
Pageof 18

Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|May 17, 2023
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitorsWilliam Shaffer, Ikei S Kobayashi, Daniel Sentana-Lledo, et al.
Blood|February 18, 2010
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cellsBritta Will, Tanya Siddiqi, Meritxell Alberich Jordà, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2007
Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590Daniel B Costa, Sigui Li, Olivier Kocher, et al.
The Journal of Infection|January 26, 2005
Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patientsSandra H A Bonon, Silvia M F Menoni, Cláudio L Rossi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungAndrew M Brunner, Daniel B Costa, Rebecca S Heist, et al.
Plos One|March 14, 2015
CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinomaYi Cai, Ayako Hirata, Sohei Nakayama, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2008
Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian populationHelen N Honma, Eduardo M De Capitani, Maurício W Perroud, et al.
Clinical Lung Cancer|April 26, 2015
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-ReviewSamuel J Klempner, Sai-Hong Ignatius Ou, Daniel B Costa, et al.
Targeted Oncology|May 6, 2014
EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patientsHelen N Honma, Maurício W Perroud, Maurício S T Leme, et al.
JTO Clinical and Research Reports|June 9, 2021
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsPedro E N S Vasconcelos, Carol Gergis, Hollis Viray, et al.
Pageof 18